In the United States, the<unk>  <unk>  is a prescription drug term referring to the<unk><unk>  for medications offered at the<unk>  level. The metric was originally intended to convey real<unk> ng information to third-party payers, including government prescription drug programs. Commercial publishers of drug<unk> ng data such as Red Book have published<unk>  data since at least 1970. The<unk> ng information is "based on data obtained from manufacturers, distributors, and other suppliers." However, despite the data source, published<unk> s are generally inflated by 20% relative to actual market<unk> s or<unk>  acquisition cost for prescription drugs. For decades,<unk>  has been used to determine third-party reimbursement throughout the health care industry because third party payers have no other reliable method of obtaining real market<unk> s as most contracts contain confidentiality clauses. Reimbursement amounts are typically based on<unk>  minus some percentage. As a result of published<unk> s often exceeding real prescription drug<unk> s, many states have brought lawsuits against pharmaceutical manufacturers and others, alleging fraud and violations of consumer protection laws.
Average wholesale price
Case fatality rate
Mortality rate
Drug packaging
Prescription charges
Dose profile
Risk of mortality
Flexible spending account